Future investigations should aim at identifying predictive factors, mechanisms, and preventive strategies for reducing cardiotoxicity in chronic lymphocytic leukemia patients taking Bruton tyrosine kinase inhibitors. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.